Obesity: An Immunometabolic Perspective

Frontiers in Endocrinology

Volumn 7, Issue DEC, 2016, Pages

  Ray, Indrani ^a   Mahata, Sushil K ^b,c   De, Rajat K ^a  

^a INDIAN STATISTICAL INSTITUTE   (India)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ER stress; Insulin resistance; Macrophages; Non alcoholic fatty liver diseases; Obesity; Reactive oxygen species; Type 2 diabetes

Indexed keywords

FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROSTAGLANDIN,THROMBOXANE OR LEUKOTRIENE RECEPTOR AFFECTING AGENTS; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; ARTICLE; CELL POLARITY; CELL TRANSDIFFERENTIATION; HUMAN; IMMUNOLOGY; IMMUNOMETABOLISM; IMMUNOMODULATION; INNATE IMMUNITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; KUPFFER CELL; LIPOLYSIS; LIVER FIBROSIS; MACROPHAGE; METABOLIC DISORDER; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; TISSUE INJURY;

EID: 85008237767     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2016.00157     Document Type: Article

References (128)

1. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 259(5091):87-91. doi: 10.1126/science.7678183
2. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 112(12):1796-808. doi:10.1172/JCI200319246
3. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 112(12):1821-30. doi:10.1172/JCI200319451
4. Hotamisligil GS. Inflammation and metabolic disorders. Nature (2006) 444(7121):860-7. doi:10.1038/nature05485
5. Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab (2013) 17(6):851-9. doi:10.1016/j.cmet.2013.05.008
6. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med (2012) 18(3):363-74. doi:10.1038/nm.2627
7. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science (2013) 339(6116):172-7. doi:10.1126/science.1230721
8. McPhee JB, Schertzer JD. Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation. Clin Sci (Lond) (2015) 129(12):1083-96. doi:10.1042/CS20150431
9. Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol (2016) 12(1):15-28. doi:10.1038/nrendo.2015.189
10. Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol (2016) 17(6):618-25. doi:10.1038/ni.3466
11. Cousin B, Casteilla L, Laharrague P, Luche E, Lorsignol A, Cuminetti V, et al. Immuno-metabolism and adipose tissue: the key role of hematopoietic stem cells. Biochimie (2016) 124:21-6. doi:10.1016/j.biochi.2015.06.012
12. Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B, et al. Feeding our immune system: impact on metabolism. Clin Dev Immunol (2008) 2008:639803. doi:10.1155/2008/639803
13. Schaffler A, Scholmerich J. Innate immunity and adipose tissue biology. Trends Immunol (2010) 31(6):228-35. doi:10.1016/j.it.2010.03.001
14. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol (2010) 10(6):440-52. doi:10.1038/nri2782
15. Boehm T. Design principles of adaptive immune systems. Nat Rev Immunol (2011) 11(5):307-17. doi:10.1038/nri2944
16. Mbitikon-Kobo FM, Vocanson M, Michallet MC, Tomkowiak M, Cottalorda A, Angelov GS, et al. Characterization of a CD44/CD122int memory CD8 T cell subset generated under sterile inflammatory conditions. J Immunol (2009) 182(6):3846-54. doi:10.4049/jimmunol.0802438
17. Mills KH. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol (2011) 11(12):807-22. doi:10.1038/nri3095
18. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol (2010) 72:219-46. doi:10.1146/annurev-physiol-021909-135846
19. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J (2008) 22(5):1572-80. doi:10.1096/fj.07-9909com
20. Curtiss LK, Tobias PS. Emerging role of toll-like receptors in atherosclerosis. J Lipid Res (2009) 50(Suppl):S340-5. doi:10.1194/jlr.R800056-JLR200
21. Westwell-Roper C, Nackiewicz D, Dan M, Ehses JA. Toll-like receptors and NLRP3 as central regulators of pancreatic islet inflammation in type 2 diabetes. Immunol Cell Biol (2014) 92(4):314-23. doi:10.1038/icb.2014.4
22. Haneklaus M, O'Neill LA. NLRP3 at the interface of metabolism and inflammation. Immunol Rev (2015) 265(1):53-62. doi:10.1111/imr.12285
23. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest (2006) 116(11):3015-25. doi:10.1172/JCI28898
24. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol (2005) 25(10):2062-8. doi:10.1161/01.ATV.0000183883.72263.13
25. Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem (2005) 280(42):35361-71. doi:10.1074/jbc.M504611200
26. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest (2007) 117(1):175-84. doi:10.1172/JCI29881
27. Widmann JJ, Cotran RS, Fahimi HD. Mononuclear phagocytes (Kupffer cells) and endothelial cells. Identification of two functional cell types in rat liver sinusoids by endogenous peroxidase activity. J Cell Biol (1972) 52(1):159-70.
28. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331(6013):44-9. doi:10.1126/science.1198687
29. Yokoyama WM, Sojka DK, Peng H, Tian Z. Tissue-resident natural killer cells. Cold Spring Harb Symp Quant Biol (2013) 78:149-56. doi:10.1101/sqb.2013.78.020354
30. Hautekeete ML, Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch (1997) 430(3):195-207. doi:10.1007/BF01324802
31. DeLeve LD. Liver sinusoidal endothelial cells and liver regeneration. J Clin Invest (2013) 123(5):1861-6. doi:10.1172/JCI66025
32. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity (2014) 41(1):36-48. doi:10.1016/j.immuni.2014.05.010
33. Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol (2016) 13(3):267-76. doi:10.1038/cmi.2016.3
34. Devisscher L, Verhelst X, Colle I, Van Vlierberghe H, Geerts A. The role of macrophages in obesity-driven chronic liver disease. J Leukoc Biol (2016) 99(5):693-8. doi:10.1189/jlb.5RU0116-016R
35. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol (2008) 9(5):503-10. doi:10.1038/ni1582
36. Peng H, Jiang X, Chen Y, Sojka DK, Wei H, Gao X, et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest (2013) 123(4):1444-56. doi:10.1172/JCI66381
37. Fasbender F, Widera A, Hengstler JG, Watzl C. Natural killer cells and liver fibrosis. Front Immunol (2016) 7:19. doi:10.3389/fimmu.2016.00019
38. Peng H, Wisse E, Tian Z. Liver natural killer cells: subsets and roles in liver immunity. Cell Mol Immunol (2016) 13(3):328-36. doi:10.1038/cmi.2015.96
39. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol (2013) 3(2):785-97. doi:10.1002/cphy.c120026
40. Jager J, Aparicio-Vergara M, Aouadi M. Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells. J Intern Med (2016) 280(2):209-20. doi:10.1111/joim.12483
41. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol (2006) 12(46):7413-20. doi:10.3748/wjg.v12.i46.7413
42. Dey A, Allen J, Hankey-Giblin PA. Ontogeny and polarization of macrophages in inflammation: blood monocytes versus tissue macrophages. Front Immunol (2014) 5:683. doi:10.3389/fimmu.2014.00683
43. Goss JA, Mangino MJ, Callery MP, Flye MW. Prostaglandin E2 downregulates Kupffer cell production of IL-1 and IL-6 during hepatic regeneration. Am J Physiol (1993) 264(4 Pt 1):G601-8.
44. Roland CR, Goss JA, Mangino MJ, Hafenrichter D, Flye MW. Autoregulation by eicosanoids of human Kupffer cell secretory products. A study of interleukin-1, interleukin-6, tumor necrosis factor-alpha, transforming growth factor-beta, and nitric oxide. Ann Surg (1994) 219(4):389-99.
45. Henkel J, Neuschafer-Rube F, Pathe-Neuschafer-Rube A, Puschel GP. Aggravation by prostaglandin E2 of interleukin-6-dependent insulin resistance in hepatocytes. Hepatology (2009) 50(3):781-90. doi:10.1002/hep.23064
46. Henkel J, Gartner D, Dorn C, Hellerbrand C, Schanze N, Elz SR, et al. Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis. Lab Invest (2011) 91(7):1107-17. doi:10.1038/labinvest.2011.47
47. Klueh U, Czajkowski C, Ludzinska I, Qiao Y, Frailey J, Kreutzer DL. Impact of CCL2 and CCR2 chemokine/receptor deficiencies on macrophage recruitment and continuous glucose monitoring in vivo. Biosens Bioelectron (2016) 86:262-9. doi:10.1016/j.bios.2016.06.026
48. Morinaga H, Mayoral R, Heinrichsdorff J, Osborn O, Franck N, Hah N, et al. Characterization of distinct subpopulations of hepatic macrophages in HFD/obese mice. Diabetes (2015) 64(4):1120-30. doi:10.2337/db14-1238
49. Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, Weiss SJ. A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell (2006) 125(3):577-91. doi:10.1016/j.cell.2006.02.050
50. Ricard-Blum S. The collagen family. Cold Spring Harb Perspect Biol (2011) 3(1):a004978. doi:10.1101/cshperspect.a004978
51. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest (2007) 117(3):530-8. doi:10.1172/JCI30595
52. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol (2004) 4(8):583-94. doi:10.1038/nri1412
53. Buechler C, Krautbauer S, Eisinger K. Adipose tissue fibrosis. World J Diabetes (2015) 6(4):548-53. doi:10.4239/wjd.v6.i4.548
54. Luo T, Nocon A, Fry J, Sherban A, Rui X, Jiang B, et al. AMPK activation by metformin suppresses abnormal extracellular matrix remodeling in adipose tissue and ameliorates insulin resistance in obesity. Diabetes (2016) 65(8):2295-310. doi:10.2337/db15-1122
55. Mariman EC, Wang P. Adipocyte extracellular matrix composition, dynamics and role in obesity. Cell Mol Life Sci (2010) 67(8):1277-92. doi:10.1007/s00018-010-0263-4
56. Song E, Ouyang N, Horbelt M, Antus B, Wang M, Exton MS. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol (2000) 204(1):19-28. doi:10.1006/cimm.2000.1687
57. Pessin JE, Kwon H. How does high-fat diet induce adipose tissue fibrosis? J Investig Med (2012) 60(8):1147-50. doi:10.2310/JIM.0b013e318271fdb9
58. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol (2014) 15(12):786-801. doi:10.1038/nrm3904
59. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 1477(1-2):267-83. doi:10.1016/S0167-4838(99)00279-4
60. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest (1999) 104(6):777-85. doi:10.1172/JCI7325
61. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 103(6):779-88. doi:10.1172/JCI5909
62. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med (2001) 194(6):809-21. doi:10.1084/jem.194.6.809
63. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med (2006) 12(1):99-106. doi:10.1038/nm1332
64. Aliprantis AO, Wang J, Fathman JW, Lemaire R, Dorfman DM, Lafyatis R, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A (2007) 104(8):2827-30. doi:10.1073/pnas.0700021104
65. Friedman SL. Liver fibrosis -from bench to bedside. J Hepatol (2003) 38(Suppl 1):S38-53. doi:10.1016/S0168-8278(02)00429-4
66. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis (2004) 24(1):3-20. doi:10.1055/s-2004-823098
67. Sun K, Tordjman J, Clement K, Scherer PE. Fibrosis and adipose tissue dysfunction. Cell Metab (2013) 18(4):470-7. doi:10.1016/j.cmet.2013.06.016
68. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest (2005) 115(2):209-18. doi:10.1172/JCI24282
69. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol (2014) 14(3):181-94. doi:10.1038/nri3623
70. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A (1985) 82(24):8681-5. doi:10.1073/pnas.82.24.8681
71. Gabele E, Brenner DA, Rippe RA. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci (2003) 8:d69-77. doi:10.2741/887
72. Pradere JP, Kluwe J, De Minicis S, Jiao JJ, Gwak GY, Dapito DH, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology (2013) 58(4):1461-73. doi:10.1002/hep.26429
73. Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun (2004) 321(2):413-23. doi:10.1016/j.bbrc.2004.06.153
74. Lin SL, Castano AP, Nowlin BT, Lupher ML Jr, Duffield JS. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol (2009) 183(10):6733-43. doi:10.4049/jimmunol.0901473
75. Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med (2011) 184(5):569-81. doi:10.1164/rccm.201010-1719OC
76. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A (2012) 109(46):E3186-95. doi:10.1073/pnas.1119964109
77. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis (2010) 30(3):245-57. doi:10.1055/s-0030-1255354
78. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology (2009) 50(1):261-74. doi:10.1002/hep.22950
79. Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology (2005) 128(1):138-46. doi:10.1053/j.gastro.2004.10.005
80. Mitchell C, Couton D, Couty JP, Anson M, Crain AM, Bizet V, et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol (2009) 174(5):1766-75. doi:10.2353/ajpath.2009.080632
81. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut (2012) 61(3):416-26. doi:10.1136/gutjnl-2011-300304
82. Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Mockel D, et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut (2014) 63(12):1960-71. doi:10.1136/gutjnl-2013-306294
83. Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassler N, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology (2014) 59(3):1060-72. doi:10.1002/hep.26783
84. Zimmermann HW, Tacke F. In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications? Expert Rev Gastroenterol Hepatol (2015) 9(9):1139-41. doi:10.1586/17474124.2015.1063417
85. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest (2000) 106(4):473-81. doi:10.1172/JCI10842
86. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest (2003) 112(12):1785-8. doi:10.1172/JCI20514
87. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest (2005) 115(5):1111-9. doi:10.1172/JCI25102
88. Schubert KM, Scheid MP, Duronio V. Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473. J Biol Chem (2000) 275(18):13330-5. doi:10.1074/jbc.275.18.13330
89. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest (2011) 121(5):1858-70. doi:10.1172/JCI43378
90. Khan MT, Nieuwdorp M, Backhed F. Microbial modulation of insulin sensitivity. Cell Metab (2014) 20(5):753-60. doi:10.1016/j.cmet.2014.07.006
91. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science (2005) 307(5717):1915-20. doi:10.1126/science.1104816
92. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature (2006) 444(7122):1022-3. doi:10.1038/4441022a
93. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature (2012) 489(7415):242-9. doi:10.1038/nature11552
94. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 444(7122):1027-31. doi:10.1038/nature05414
95. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A (2004) 101(44):15718-23. doi:10.1073/pnas.0407076101
96. Caesar R, Reigstad CS, Backhed HK, Reinhardt C, Ketonen M, Lunden GO, et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut (2012) 61(12):1701-7. doi:10.1136/gutjnl-2011-301689
97. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med (2011) 3(9):559-72. doi:10.1002/emmm.201100159
98. Teixeira TF, Souza NC, Chiarello PG, Franceschini SC, Bressan J, Ferreira CL, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr (2012) 31(5):735-40. doi:10.1016/j.clnu.2012.02.009
99. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol (2006) 40(Suppl 1):S17-29. doi:10.1097/01.mcg.0000168645.86658.22
100. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 36(6):1349-54. doi:10.1002/hep.1840360609
101. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology (2010) 52(5):1836-46. doi:10.1002/hep.24001
102. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 140(2):197-208. doi:10.1016/j.cell.2009.12.052
103. Sleyster EC, Knook DL. Relation between localization and function of rat liver Kupffer cells. Lab Invest (1982) 47(5):484-90.
104. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. J Leukoc Biol (2001) 70(2):163-70.
105. Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol (2007) 22(4):491-7. doi:10.1111/j.1440-1746.2006.04758.x
106. Lefkowitch JH, Haythe JH, Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod Pathol (2002) 15(7):699-704. doi:10.1097/01.MP.0000019579.30842.96
107. Andres D, Sanchez-Reus I, Bautista M, Cascales M. Depletion of Kupffer cell function by gadolinium chloride attenuates thioacetamide-induced hepatotoxicity. Expression of metallothionein and HSP70. Biochem Pharmacol (2003) 66(6):917-26. doi:10.1016/S0006-2952(03)00443-X
108. Muriel P, Escobar Y. Kupffer cells are responsible for liver cirrhosis induced by carbon tetrachloride. J Appl Toxicol (2003) 23(2):103-8. doi:10.1002/jat.892
109. Zhong Z, Connor HD, Mason RP, Qu W, Gao W, Lemasters JJ, et al. Role of Kupffer cells in reperfusion injury in fat-loaded livers from ethanol-treated rats. J Pharmacol Exp Ther (1995) 275(3):1512-7.
110. Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH, et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 175(11):7661-8. doi:10.4049/jimmunol.175.11.7661
111. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol (2007) 47(4):571-9. doi:10.1016/j.jhep.2007.04.019
112. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci (2008) 1(1):36-43. doi:10.1111/j.1752-8062.2008.00026.x
113. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med (2010) 152(6):346-57. doi:10.7326/0003-4819-152-6-201003160-00004
114. Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia (2013) 56(4):714-23. doi:10.1007/s00125-012-2819-3
115. Barzilay JI, Jablonski KA, Fonseca V, Shoelson SE, Goldfine AB, Strauch C, et al. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. Diabetes Care (2014) 37(4):1083-91. doi:10.2337/dc13-1527
116. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab (2011) 96(1):E146-50. doi:10.1210/jc.2010-1170
117. Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1beta antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab (2013) 39(6):524-31. doi:10.1016/j.diabet.2013.07.003
118. Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care (2012) 35(8):1654-62. doi:10.2337/dc11-2219
119. Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care (2013) 36(8):2239-46. doi:10.2337/dc12-1835
120. Esterson YB, Zhang K, Koppaka S, Kehlenbrink S, Kishore P, Raghavan P, et al. Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. J Investig Med (2013) 61(8):1152-60. doi:10.2310/JIM.0000000000000017
121. Koppaka S, Kehlenbrink S, Carey M, Li W, Sanchez E, Lee DE, et al. Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans. Diabetes (2013) 62(6):1843-54. doi:10.2337/db12-0868
122. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med (2013) 19(5):557-66. doi:10.1038/nm.3159
123. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell (2012) 148(3):556-67. doi:10.1016/j.cell.2011.11.062
124. Haynes AC, Chapman H, Taylor C, Moore GB, Cawthorne MA, Tadayyon M, et al. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept (2002) 104(1-3):153-9. doi:10.1016/S0167-0115(01)00358-5
125. Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP. OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Front Neurosci (2014) 8:57. doi:10.3389/fnins.2014.00057
126. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell (2010) 142(5):687-98. doi:10.1016/j.cell.2010.07.041
127. Spencer M, Finlin BS, Unal R, Zhu B, Morris AJ, Shipp LR, et al. Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. Diabetes (2013) 62(5):1709-17. doi:10.2337/db12-1042
128. Tousoulis D, Plastiras A, Siasos G, Oikonomou E, Verveniotis A, Kokkou E, et al. Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome. Atherosclerosis (2014) 232(1):10-6. doi:10.1016/j.atherosclerosis.2013.10.014